Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $164.96, for a total value of $247,440.00. Following the transaction, the chief executive officer now directly owns 323,341 shares in the company, valued at approximately $53,338,331.36. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ JAZZ opened at $161.93 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.84 and a current ratio of 3.98. Jazz Pharmaceuticals plc has a fifty-two week low of $101.81 and a fifty-two week high of $178.64. The firm has a market capitalization of $9.12 billion, a PE ratio of 51.08, a price-to-earnings-growth ratio of 4.64 and a beta of 1.08. The stock’s 50-day simple moving average is $166.13 and its 200-day simple moving average is $156.03.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 23rd. The specialty pharmaceutical company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.58 by $0.42. Jazz Pharmaceuticals had a return on equity of 20.16% and a net margin of 7.86%. The business had revenue of $665.52 million for the quarter, compared to analyst estimates of $639.83 million. During the same quarter last year, the company earned $4.42 EPS. The business’s quarterly revenue was up 14.4% on a year-over-year basis. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 10.83 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in Jazz Pharmaceuticals by 41.0% during the 4th quarter. CWM LLC now owns 258 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 75 shares during the last quarter. Captrust Financial Advisors grew its stake in Jazz Pharmaceuticals by 4.1% during the 4th quarter. Captrust Financial Advisors now owns 2,820 shares of the specialty pharmaceutical company’s stock worth $465,000 after buying an additional 110 shares during the last quarter. Kendall Capital Management grew its stake in Jazz Pharmaceuticals by 1.7% during the 4th quarter. Kendall Capital Management now owns 7,275 shares of the specialty pharmaceutical company’s stock worth $1,201,000 after buying an additional 125 shares during the last quarter. Bessemer Group Inc. grew its stake in Jazz Pharmaceuticals by 9.1% during the 4th quarter. Bessemer Group Inc. now owns 1,912 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 159 shares during the last quarter. Finally, NEXT Financial Group Inc purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 95.67% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.
Read More: Why is insider trading harmful?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.